Epstein Files Search

Dataset

Sort

Status

DOJ Status

Date Range

–

Page Count

–

Corpus: 1990-03-17 – 2025-12-01

December 2025

Mo

Tu

We

Th

Fr

Sa

Su

None

Light

Medium

Heavy

Results by Dataset5 total

Set 9

4

Set 11

1

5 results for “"Rational Drug Design"”

EFTA00586852Set 9

Keyboard Shortcuts

/

Focus search

Esc

Blur input

O

Open PDF

←→

Paginate

90p36,976w

invent and apply a physics- based approach that establishes a new standard for rational drug design The principals invested S2.3M (Fully-Diluted Equity Ownership: —7.0%) in November 2012. Other Investors

https://www.justice.gov/epstein/files/DataSet%209/EFTA00586852.pdf

EFTA00587585Set 9

5p1,033w

acquisition team. Price Waterhouse Technology Center: Created and delivered seminar presentation on Rational Drug Design and the potential cost savings for the pharmaceutical Industry. Engaged by Director. Pharmacia Corporation: Evaluated

https://www.justice.gov/epstein/files/DataSet%209/EFTA00587585.pdf

EFTA02444555Set 11

2006-03-1726p10,426w

centered on adhesion of mammalian cells, viruses, and bacteria to surfaces, polyvalency, and rational drug design, and biophysical studies centered around capillary electrophoresis and surface plasmon resonance spectroscopy. Those concerned

https://www.justice.gov/epstein/files/DataSet%2011/EFTA02444555.pdf

EFTA00868111Set 9

2014-12-154p611w

manifestations. As such they carry immense potential for EFTA00868111 understanding human biology and rational drug design." — Erwin Neher, Nobel Prize in Medicine

https://www.justice.gov/epstein/files/DataSet%209/EFTA00868111.pdf

EFTA01103465Set 9

2013-12-0230p11,241w

therapy interventions for age-associated and other diseases. — Integration of AGI software with rational drug design software to enable creation of novel molecules targeting combinations of genes highlighted

https://www.justice.gov/epstein/files/DataSet%209/EFTA01103465.pdf